<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05112640</url>
  </required_header>
  <id_info>
    <org_study_id>21-0045</org_study_id>
    <nct_id>NCT05112640</nct_id>
  </id_info>
  <brief_title>Subcuticular Absorbable Staples Versus Conventional Skin Closure in Women Undergoing Cesarean Delivery</brief_title>
  <official_title>Subcuticular Absorbable Staples Versus Conventional Skin Closure in Women Undergoing Cesarean Delivery: A Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cooper Companies</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite the high numbers of cesareans being performed, scientific evidence behind which&#xD;
      surgical techniques are best remains uncertain. Our objective is to determine if subcuticular&#xD;
      absorbable staples improve operative time and wound cosmetics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be an open-label randomized controlled clinical trial. Women undergoing cesarean&#xD;
      delivery will be randomized to have either standard wound closure with Monocryl suture or&#xD;
      absorbable subcuticular staples placed by INSORB skin stapling device. The INSORB under the&#xD;
      skin stapling device is FDA approved but not currently used as standard of care at UTMB. We&#xD;
      will exclude women with intraamniotic infection, immunosuppression, active skin infection,&#xD;
      those unlikely to be followed-up after delivery, or unable to provide consent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects who agree to participate in the study will be randomized to one of the two groups below in a 1/1 allocation</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Reviewers of wound cosmetics during the post operative time will be blind to the intervention. However, surgeon at the time skin closure and patient will not be blinded to the intervention.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Operating time</measure>
    <time_frame>Start of surgery through end of skin closure</time_frame>
    <description>Total time for the procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wound cosmesis</measure>
    <time_frame>Time of surgery through six weeks post partum</time_frame>
    <description>A digital photograph of the incision will be obtained on wound check visit POD 5-10 days and 4-6 weeks postoperative. Each photograph will be evaluated according to objective criteria (width, elevation, color, marks, and general appearance) by independent blinded research staff</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite wound complication</measure>
    <time_frame>Time of surgery through six weeks post partum</time_frame>
    <description>Hematoma, seroma, dehiscence, breakdown of wound, wound infection, endometritis, sepsis, post part fevers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post operative pain</measure>
    <time_frame>Time of surgery through six weeks post partum</time_frame>
    <description>Pain scale ranging from 0-10 on postoperative days 1 to 3 as well as at wound check visit recorded by nursing staff</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Time of surgery through six weeks post partum</time_frame>
    <description>Allergic reactions: anaphylaxis, angioedema, skin rashes, including Stevens Johnson and Toxic Epidermal Necrolysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of resources</measure>
    <time_frame>Time of surgery through six weeks post partum</time_frame>
    <description>Hospital stay, postpartum clinic or emergency room visit within 30 days of delivery, need for imaging or other invasive procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>Time of surgery through six weeks post partum</time_frame>
    <description>Questionnaire POD 2-3 (before discharge) and at wound check visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">316</enrollment>
  <condition>Operative Time</condition>
  <condition>Wound Heal</condition>
  <arm_group>
    <arm_group_label>Suture wound closure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Absorbable sutures for closure of cesarean skin incision using Monocryl manufactured by Ethicon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Absorbable staple wound closure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Staples will be applied as per the manufacturer's instructions intraoperatively using INSORB device manufactured by Cooper Surgical.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>INSORB: subcuticular stapling device</intervention_name>
    <description>Under the skin stapling device that delivers absorbable staples</description>
    <arm_group_label>Absorbable staple wound closure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Subcuticular monocryl suture manufactured by Ethicon</intervention_name>
    <description>Under the skin suture placed by hand</description>
    <arm_group_label>Suture wound closure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-50 years of age&#xD;
&#xD;
          -  Women ≥ 24 weeks viable gestation&#xD;
&#xD;
          -  Will be undergoing cesarean delivery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient unwilling or unable to provide consent.&#xD;
&#xD;
          -  No or very limited prenatal care or a non-resident patient who is unlikely to&#xD;
             follow-up after delivery.&#xD;
&#xD;
          -  Immunosuppressed subjects: i.e., taking systemic immunosuppressant or steroids (e.g.&#xD;
             transplant subjects; not including steroids for lung maturity), HIV with CD4 &lt;200, or&#xD;
             other&#xD;
&#xD;
          -  Decision not to have skin closure (e.g. secondary wound closure, mesh closure)&#xD;
&#xD;
          -  Current skin infection&#xD;
&#xD;
          -  Coagulopathy&#xD;
&#xD;
          -  High likelihood of additional surgical procedure beyond cesarean (e.g. scheduled&#xD;
             hysterectomy, tubal ligation, bowel or adnexal surgery)&#xD;
&#xD;
          -  Incarcerated individuals&#xD;
&#xD;
          -  Intraamniotic infection&#xD;
&#xD;
          -  Subjects participating on other treatment trials or studies that would interfere with&#xD;
             the current study's primary outcome.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Saade, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division Director/Co-PI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brett Goldman, MD</last_name>
    <phone>9542632359</phone>
    <email>brgoldma@utmb.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antonio Saad, MD</last_name>
    <phone>4097720982</phone>
    <email>afsaad@utmb.edu</email>
  </overall_contact_backup>
  <reference>
    <citation>Frishman GN, Schwartz T, Hogan JW. Closure of Pfannenstiel skin incisions. Staples vs. subcuticular suture. J Reprod Med. 1997 Oct;42(10):627-30.</citation>
    <PMID>9350017</PMID>
  </reference>
  <reference>
    <citation>Gaertner I, Burkhardt T, Beinder E. Scar appearance of different skin and subcutaneous tissue closure techniques in caesarean section: a randomized study. Eur J Obstet Gynecol Reprod Biol. 2008 May;138(1):29-33. Epub 2007 Sep 6.</citation>
    <PMID>17825472</PMID>
  </reference>
  <reference>
    <citation>Rousseau JA, Girard K, Turcot-Lemay L, Thomas N. A randomized study comparing skin closure in cesarean sections: staples vs subcuticular sutures. Am J Obstet Gynecol. 2009 Mar;200(3):265.e1-4. doi: 10.1016/j.ajog.2009.01.019.</citation>
    <PMID>19254586</PMID>
  </reference>
  <reference>
    <citation>Fick JL, Novo RE, Kirchhof N. Comparison of gross and histologic tissue responses of skin incisions closed by use of absorbable subcuticular staples, cutaneous metal staples, and polyglactin 910 suture in pigs. Am J Vet Res. 2005 Nov;66(11):1975-84.</citation>
    <PMID>16334959</PMID>
  </reference>
  <reference>
    <citation>Piñeros-Fernandez A, Salopek LS, Rodeheaver PF, Drake DB, Edlich RF, Rodeheaver GT. A revolutionary advance in skin closure compared to current methods. J Long Term Eff Med Implants. 2006;16(1):19-27.</citation>
    <PMID>16566742</PMID>
  </reference>
  <reference>
    <citation>Nitsche J, Howell C, Howell T. Skin closure with subcuticular absorbable staples after cesarean section is associated with decreased analgesic use. Arch Gynecol Obstet. 2012 Apr;285(4):979-83. doi: 10.1007/s00404-011-2121-5. Epub 2011 Oct 30.</citation>
    <PMID>22037686</PMID>
  </reference>
  <reference>
    <citation>Schrufer-Poland TL, Ruiz MP, Kassar S, Tomassian C, Algren SD, Yeast JD. Incidence of wound complications in cesarean deliveries following closure with absorbable subcuticular staples versus conventional skin closure techniques. Eur J Obstet Gynecol Reprod Biol. 2016 Nov;206:53-56. doi: 10.1016/j.ejogrb.2016.07.501. Epub 2016 Aug 3.</citation>
    <PMID>27632411</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 13, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Medical Branch, Galveston</investigator_affiliation>
    <investigator_full_name>Goldman, Brett R</investigator_full_name>
    <investigator_title>Fellow Physician</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Do not plan to share IPD.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

